The Quantellect read.As of Nov 19, 2026, 3 active firms cover Atossa Genetics Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $12.00 to $25.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $20.67 sits 1042% above the current $1.81. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees revenue growth near 0% this year and 0% next, consensus EPS building from about $-0.83 next quarter toward $-3.30 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$20.67
+1041.8% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.81 current
Highest Target$25.00
Average Target$20.67
Lowest Target$12.00
Detailed analyst forecasts for ATOS
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate ATOS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
ATOS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.83
Range $-0.83 – $-0.83 · 1 analysts · -25% YoY
Next period, 1 analysts expect Atossa Genetics Inc to earn $-0.83 a share (range $-0.83 – $-0.83), versus $-1.11 a year earlier. Full-year consensus is $-3.56, growing to $-3.30 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $0 next year.
Top analysts covering Atossa Genetics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ATOS.
#1
Emily Bodnar
HC Wainwright & Co. · Rank #521
Buy
$25.00+1281.2% to target
Overall win rate
24%
+ Follow
#2
Edward Woo
Ascendiant Capital · Rank #570
Buy
$25.00+1281.2% to target
Overall win rate
24%
+ Follow
#3
AL
Albert Lowe
Craig-Hallum
Buy
$10.00+452.5% to target
Coverage
—
+ Follow
#4
MK
Michael King
Rodman & Renshaw
Buy
$12.00+563.0% to target
Coverage
—
+ Follow
#5
MG
Michael G. King Jr.
Rodman & Renshaw
Buy
$12.00+563.0% to target
Coverage
—
+ Follow
ATOS stock forecast FAQ
What is ATOS's average 12-month price target?+
The 3 active firms with a live target average $20.67 for Atossa Genetics Inc over the next 12 months, ranging from a $25.00 high to a $12.00 low, as of Nov 19, 2026.
Is ATOS stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for ATOS?+
The Street-high target is $25.00 (Ascendiant Capital), and the Street-low is $12.00 (Rodman & Renshaw). The average of all 3 active-firm targets is $20.67.
How many active Wall Street firms cover ATOS?+
3 active firms have a recognized rating on Atossa Genetics Inc as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering ATOS?+
Among analysts who currently cover ATOS, Emily Bodnar of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #521). Their current call is Buy with a $25.00 target.
What is Atossa Genetics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.83 per share (range $-0.83 – $-0.83) across 1 analysts. Full-year EPS is projected at $-3.56, rising to $-3.30 the following year.
How much revenue is Atossa Genetics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading ATOS lately?+
As of Nov 19, 2026, 3 of 3 active firms rate ATOS a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ATOS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.